Quinolone Research Articles

Quinolone- and Macrolide-Resistant Gonorrhea Emerge

The increasing popularity of nonculture methods for diagnosing gonorrhea in the U.S. means that local changes in antibiotic susceptibility may not

New uses for new and old quinolones and the challenge of resistance.

New uses for new and old quinolones and the challenge of resistance.

O-31 - Effect of new quinolones on neutrophils

O-31 - Effect of new quinolones on neutrophils

The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.

In the present study, we investigated the interactions between antibiotics, especially beta-lactam antibiotics, and rat renal organic anion transporter 1 (OAT1). [(14)C]p-Aminohippurate (PAH) uptake via OAT1 expressed in Xenopus laevis oocytes was inhibited by all of the penicillins and cephalosporins tested. Penicillin G, carbenicillin, cephaloridine, cephalothin, cefazolin, and cephalexin inhibited [(14)C]PAH uptake via OAT1 in a competitive manner (K(i) = 0.29-2.33 mM). Cinoxacin, a quinolone gyrase inhibitor, also inhibited PAH uptake via OAT1. Other antibiotics, such as gentamicin, streptomycin, and vancomycin, which do not contain anionic moieties, did not interact with OAT1. [(3)H]Penicillin G and [(14)C]cephaloridine were demonstrated to be transported via OAT1. Using the cells that stably expressed OAT1, we analyzed the cytotoxicity of several beta-lactam antibiotics. Cells expressing OAT1 showed higher susceptibility to cephaloridine (a potentially nephrotoxic beta-lactam antibiotic) toxicity than did control cells. The present study suggests that OAT1 is the major organic anion transporter in the kidney that is responsible for the renal secretion of antibiotics, especially that of beta-lactam antibiotics. Furthermore, the culture cell system expressing OAT1 was revealed to be useful for the prediction of the nephrotoxicity of beta-lactam antibiotics.

Will pneumococci put quinolones in their place?

Will pneumococci put quinolones in their place?

Synthesis of the Novel Tetrahydro-pyrrolo[2,3-c]quinolone System by Oxidation of 1,2,3,4-Tetrahydro-β-carboline

Synthesis of the Novel Tetrahydro-pyrrolo[2,3-c]quinolone System by Oxidation of 1,2,3,4-Tetrahydro-β-carboline

Mutational Resistance to Quinolones in Staphylococci

Mutational Resistance to Quinolones in Staphylococci

Enteroaggregative E. coli -- Another Problem for Travelers

Enteroaggregative Escherichia coli is the most recently recognized subgroup of E. coli to be associated with human diarrheal illness. A new article provides a picture of the clinical signs and symptoms in travelers infected with this agent and suggests a role for quinolone therapy. The article …

Quinolone-Resistant Gonorrhea Emerging in U.S..

During the last 20 years, the gonococcus has evolved significant resistance first to the penicillins, then to the tetracyclines. Now the quinolones

Quinolones ??? no increased risk of teratogenecity

Quinolones ??? no increased risk of teratogenecity

Attempts to assess the economics of quinolones in Canada

Attempts to assess the economics of quinolones in Canada

Attempts to assess the economics of quinolones in Canada

Attempts to assess the economics of quinolones in Canada

Classification of quinolones by V. Andriole

Classification of quinolones by V. Andriole

Conversion of a 4-quinolone into a 1,6-diazaphenalene

Abstract 5,8-Dimethoxyquinolin-4-one has been transformed in five steps into a 7-oxo-1,6-diazaphenalene and in 4 steps into 6-aza-1-oxaphenalene.

S23-3 - Design and Synthesis of Next Generation of New Quinolone — In the case of DU-6859a

S23-3 - Design and Synthesis of Next Generation of New Quinolone — In the case of DU-6859a

Quinolones in patients with neutropenia and cancer

Quinolones in patients with neutropenia and cancer

Structure of two quinolones and a study on the lasing efficiency of these compounds

Structure of two quinolones and a study on the lasing efficiency of these compounds

Resistance to quinolones in mycobacteria

La lèpre ou maladie de Hansen est une maladie décrite depuis plus de 2 millénaires qui est toujours présente à travers le monde. Plus de 200 000 nouveaux cas sont rapportés chaque année par l’OMS, principalement en Inde, au Brésil et en Indonésie. La découverte de la dapsone (1941) a permis d’espérer guérir la lèpre. Le schéma thérapeutique, recommandé en 1981 par l’OMS, est une polychimiothérapie associant la dapsone, la rifampicine et la clofazimine pendant une durée de 6 à 12 mois selon les formes de la maladie. Un traitement minute pour les formes à lésion unique par rifampicine, ofloxacine et minocycline est recommandé depuis 1997. La standardisation du traitement antibiotique permet d’optimiser la prise en charge dans les régions endémiques, souvent peu accessibles médicalement. Il est nécessaire d’avoir aussi d’autres molécules actives comme l’ofloxacine, la minocycline, et la clarithromycine qui sont utilisées pour les cas dus à des souches résistantes. Mycobacterium leprae, qui est la mycobactérie responsable de cette maladie, a la particularité de se multiplier très lentement et de ne pas cultiver in vitro, ce qui oblige à tester l’activité des antibiotiques chez la souris et a conduit au développement des tests moléculaires pour détecter la résistance.Leprosy or Hansen's disease, described for over two millennia, is still present worldwide. WHO reported each year more than 200,000 new cases, mainly in India, Brazil and Indonesia. The dapsone discovery (1941) allowed to hope curing leprosy. The standard treatment regimen recommended by WHO in 1981, is a combination of dapsone, rifampicin and clofazimine for a period of 6 to 12 months according to the classification of the disease. Since 1997, a single dose of rifampicin, ofloxacin and minocycline is recommended for single lesion leprosy. Standardization of antibiotic treatment allows the optimization of the disease management in endemic areas, which are often poorly accessible. For resistant strains, second line antileprosy drugs such as ofloxacin, minocycline, and clarithromycin can be used. Mycobacterium leprae, the mycobacterium responsible for this disease, has the particularity to grow very slowly without the ability to grow in vitro. Therefore, a murine model is necessary to test the activity of antibiotics against M. leprae whereas the development of molecular tests improves the detection of antibiotics resistance.

Bisphosphonate-linked quinolones and sulphonamides with affinity to hydroxylapatite

Bisphosphonate-linked quinolones and sulphonamides with affinity to hydroxylapatite

Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae.

Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae.